Bevacizumab (Avastin, Roche) is a vascular endothelial growth factor A (VEGFA) monoclonal antibody, which inhibits tumor angiogenesis, and is widely used in colorectal cancer and lung adenocarcinoma. The gene discussed is VEGFA; the disease is colorectal cancer.